Search - tctmd.com

Displaying 61 - 80 of 236

Sort: Relevancy | Date

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Features

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Shelley Wood

May 05, 2017

News Daily News

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Shelley Wood

May 03, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

Presentation

Economic Outcomes of Absorb BVSvs Everolimus-Eluting Stents in PCI

April 18, 2017

News Daily News

Absorb BVS Use Restricted in Europe

Michael O'Riordan

April 06, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

Presentation ACC 2017

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Presenter: Stephen G. Ellis

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Daily News

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

L.A. McKeown

March 02, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

Presentation JIM 2017

Perspectives on the ABSORB Randomized Trials: Take-home Messages for the Clinical Practitioner

Presenter: Gregg W. Stone

February 08, 2017

Presentation JIM 2017

ABSORB Lessons From Registries: Outcome Influenced by Experience and Technique

Presenter: Robert-Jan van Geuns

February 08, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

News Daily News

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Yael L. Maxwell

December 23, 2016

Presentation

Efficacy and Safety of the Absorb Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Absorb Diabetic Substudy

Presenter: D. Kereiakes

December 23, 2016

News Industry News

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

November 29, 2016

Presentation Cardiovascular Interventions 2016

Understanding the ABSORB Bioresorbable Vascular Scaffold: The Next Revolution in PCI

Presenter: David G. Rizik

November 10, 2016

Advertisement

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Economic Outcomes of Absorb BVSvs Everolimus-Eluting Stents in PCI

Absorb BVS Use Restricted in Europe

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Perspectives on the ABSORB Randomized Trials: Take-home Messages for the Clinical Practitioner

ABSORB Lessons From Registries: Outcome Influenced by Experience and Technique

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Efficacy and Safety of the Absorb Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Absorb Diabetic Substudy

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

Understanding the ABSORB Bioresorbable Vascular Scaffold: The Next Revolution in PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content